Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Valganciclovir Syrup vs Tablets in Kidney Transplant Recipients
NCT00275314Phase 3Terminated
- Sponsor
- University of Pittsburgh
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of valganciclovir in cytomegalovirus infection (CMV) (3 arms), sponsored by University of Pittsburgh. Primary endpoint: Bioequivalence of ganciclovir from Valganciclovir tutti-frutti syrup vs tablet. Started Feb 2006; status: terminated.
02
Drugs
valganciclovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT00275314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00275314.